The manufacturer of the specific Lorbrexen 100 mg product is Everest Pharmaceuticals Ltd.
This should remain separate from the documented development history of lorlatinib.
Pfizer and lorlatinib
Pfizer states that lorlatinib was discovered and developed by Pfizer scientists. The company developed it as a next-generation ALK inhibitor intended to address resistance to earlier ALK therapies and penetrate the blood-brain barrier.
LORBRENA
LORBRENA is the U.S. commercial brand for lorlatinib. Pfizer received its original U.S. approval in 2018 and later expanded its approval to first-line treatment of metastatic ALK-positive NSCLC in 2021.
Lorviqua
Lorviqua is the European brand for lorlatinib. The EMA identifies Pfizer Europe MA EEIG as its marketing authorization holder.
These relationships do not establish Lorbrexen’s manufacturer
The existence of Pfizer’s role as developer and reference-product company does not establish that Pfizer manufactures or markets Lorbrexen.